Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Building on the success of Bristol-Myers Squibb / Ono Pharmaceutical’s PD-1 inhibitor, Opdivo, in the recurrent renal cell carcinoma (RCC) setting, combination regimens that include immune checkpoint inhibitors, including Opdivo plus Yervoy, look set to revolutionize the treatment of advanced disease. Angiogenesis inhibitors remain a key feature in RCC treatment with Exelixis /Ipsen’s Cabometyx joining Pfizer’s Sutent and Novartis’s Votrient as a first-line treatment. The entry and increased market share of Cabometyx and Opdivo in this setting is beginning to shift Pfizer’s Inlyta, the combination of Eisai’s Lenvima / Kisplyx with Novartis’s Afinitor, and single-agent mTOR inhibitors to later lines. Furthermore, following Sutent’s approval for high-risk early-stage (stage I-III) patients in the United States, multiple immune checkpoint inhibitors are also anticipated to transition into early-stage treatments. With the highly competitive RCC market becoming increasingly fragmented, the developer of an efficacious therapy could reap high commercial rewards.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: Twenty country-specific interviews with thought leaders (medical oncologists and urologists).
Key companies: Bristol-Myers Squibb/Ono Pharmaceutical, Merck & Co./MSD, Exelixis/Ipsen, and Pfizer.
Key drugs: Opdivo, Keytruda, Cabometyx, and Inlyta.
Population segments in market forecast: Early-stage (stage I-III) renal cell carcinoma, first-line advanced or metastatic renal cell carcinoma, second-line advanced or metastatic renal cell carcinoma, third-line advanced or metastatic renal cell carcinoma, and fourth-line advanced or metastatic renal cell carcinoma.
Emerging therapies: Phase III: 8 drugs; Phase II: 18 drugs; coverage of select Phase I and preclinical products.
Already a Client? Log in to access this report.
Joshua Dawkins, , is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Dawkins obtained his doctorate in molecular biology at the Barts Cancer Institute, Queen Mary University of London, where he investigated the roles of epigenetic histone modifiers in pancreatic ductal adenocarcinoma. Dr. Dawkins also holds a Master of Pharmacology degree awarded by the University of Bath, and completed a one-year professional placement within the oncology team at MedImmune.
Ema is an epidemiologist with expertise in forecasting incident and prevalent populations within oncology, as well as some cardiovascular indications such as venous thromboembolism. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables. She completed her master’s and doctoral degree (MPH, ) in Environmental Health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes including central nervous system cancer, cognitive function, and birth outcomes.
Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.